We are live on ! Find out more
CIP

Champlain Investment Partners Portfolio holdings

AUM $7.88B
1-Year Est. Return 6.82%
This Fund
S&P 500
This Quarter Est. Return
+9.14%
1 Year Est. Return
+6.82%
3 Year Est. Return
+32.7%
5 Year Est. Return
+41.26%
10 Year Est. Return
+331.36%
AUM
$21B
AUM Growth
+$1.82B
Cap. Flow
+$406M
Cap. Flow %
1.93%
Top 10 Hldgs %
18.08%
Holding
144
New
8
Increased
70
Reduced
59
Closed
5

Top Buys

Rank Stock Value
1
STE icon
Steris
STE
+$339M
2
PLAN
Anaplan, Inc.
PLAN
+$138M
3
CSGP icon
CoStar Group
CSGP
+$86M
4
MRVI icon
Maravai LifeSciences
MRVI
+$67.7M
5
LESL icon
Leslie's
LESL
+$67.2M

Sector Composition

Rank Sector Weight
1 Healthcare 24.84%
2 Technology 20.7%
3 Industrials 14.5%
4 Consumer Staples 12.97%
5 Financials 12.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MDLA
1
DELISTED
Medallia, Inc.
MDLA
$447M 2.13%
13,257,465
-14,740
-0.1% -$424K
IART icon
2
Integra LifeSciences
IART
$1.28B
$444M 2.11%
6,510,030
-19,145
-0.3% -$1.35M
ASAN icon
3
Asana
ASAN
$1.95B
$401M 1.9%
6,460,685
+1,416,035
+28% +$54.6M
AME icon
4
Ametek
AME
$54.1B
$395M 1.88%
2,959,215
-8,320
-0.3% -$1.11M
FTV icon
5
Fortive
FTV
$18.1B
$386M 1.83%
7,345,190
-14,126
-0.2% -$761K
WDAY icon
6
Workday
WDAY
$41.4B
$354M 1.68%
1,482,475
+3,925
+0.3% +$944K
AAP icon
7
Advance Auto Parts
AAP
$3.5B
$349M 1.66%
1,702,605
+780
+0% +$153K
WAT icon
8
Waters Corp
WAT
$37.2B
$349M 1.66%
1,010,550
+23,475
+2% +$7.43M
STE icon
9
Steris
STE
$22.9B
$348M 1.65%
+1,685,437
New +$339M
EW icon
10
Edwards Lifesciences
EW
$49.3B
$329M 1.57%
3,179,127
-16,080
-0.5% -$1.52M
EG icon
11
Everest Group
EG
$15.6B
$322M 1.53%
1,276,235
+60
+0% +$15.6K
GNRC icon
12
Generac Holdings
GNRC
$11.5B
$321M 1.53%
773,355
+92,983
+14% +$31.2M
NEWR
13
DELISTED
New Relic, Inc.
NEWR
$319M 1.51%
4,757,920
-7,590
-0.2% -$489K
P
14
Everpure Inc
P
$23.1B
$315M 1.5%
16,119,765
+1,395,798
+9% +$27.4M
AJG icon
15
Arthur J. Gallagher & Co
AJG
$69.1B
$313M 1.49%
2,235,098
-61,675
-3% -$8.72M
XRAY icon
16
Dentsply Sirona
XRAY
$2.84B
$308M 1.46%
4,870,400
+4,670
+0.1% +$308K
PANW icon
17
Palo Alto Networks
PANW
$256B
$277M 1.32%
4,486,410
+8,850
+0.2% +$524K
HSY icon
18
Hershey
HSY
$37.3B
$277M 1.32%
1,591,325
-87,480
-5% -$14.7M
MASI
19
DELISTED
Masimo
MASI
$270M 1.28%
1,113,407
+141,445
+15% +$32.3M
ALGN icon
20
Align Technology
ALGN
$12.8B
$270M 1.28%
441,186
+45
+0% +$26.6K
ATR icon
21
AptarGroup
ATR
$8.69B
$267M 1.27%
1,893,910
-6,555
-0.3% -$966K
SJM icon
22
J.M. Smucker
SJM
$13.6B
$266M 1.26%
2,052,940
-122,885
-6% -$16.3M
MZTI
23
The Marzetti Company
MZTI
$3.03B
$255M 1.21%
1,315,888
-2,755
-0.2% -$517K
TW icon
24
Tradeweb Markets
TW
$23B
$254M 1.21%
2,999,395
-531,460
-15% -$43.4M
CLX icon
25
Clorox
CLX
$12B
$251M 1.19%
1,395,525
+356,260
+34% +$65M

Similar funds

Champlain Investment Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Champlain Investment Partners held 144 positions worth $21B, up 9.5% from $19.2B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Champlain Investment Partners's Q2 2021 filing shows 8 new, 70 increased, 59 reduced and 5 closed positions. Its largest new stake was Steris: 1,685,437 shares worth $348M. The largest sale was Cantel Medical Corporation, an estimated $320M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 25% a quarter earlier, followed by Technology and Industrials.

  • Champlain Investment Partners's largest Q2 2021 buy was Steris: 1,685,437 shares worth $348M.
  • Champlain Investment Partners added most to Maravai LifeSciences in Q2 2021, an estimated $67.7M increase.
  • Champlain Investment Partners's biggest Q2 2021 reduction was Ulta Beauty, cutting an estimated $63.1M.
  • Champlain Investment Partners fully exited Cantel Medical Corporation in Q2 2021, selling an estimated $320M.
  • Champlain Investment Partners's ten largest holdings make up 18% of its $21B portfolio in Q2 2021.
  • Champlain Investment Partners opened 8 new positions and closed 5 in Q2 2021.
  • Champlain Investment Partners's portfolio value rose 9.5% quarter-over-quarter to $21B.

Based on Champlain Investment Partners's 13F filing for Q2 2021, filed 12 Aug 2021.